Plain-English translation of NCT07370597 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This trial is studying whether special imaging measurements taken after the first dose of Lutetium-177 PSMA radioligand therapy can predict whether men with advanced prostate cancer will respond to treatment. The goal is to help doctors figure out early on if this medication is working for you, so they can adjust your treatment plan if needed.
Not all men respond equally well to this radioactive therapy — some see great results while others don't respond at all. Researchers believe that by measuring exactly how much radiation reaches the cancer tumors, they can predict who will benefit and potentially adjust doses to help more patients succeed.
You likely qualify if…
You likely don't qualify if…
You would receive the standard Lutetium-177 PSMA treatment as planned, with additional imaging scans (SPECT/CT and PET/CT) performed after your first treatment dose to measure radiation dose to your tumors. These scans help researchers predict how well your body will respond to the therapy, and the information may eventually help doctors personalize treatment for future patients.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Belgium